IM Cannabis (IMCC) vs Regencell Bioscience (RGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Head-to-head
| Metric | IMCC | RGC |
|---|---|---|
| Share price | $1.88 | $7.23 |
| Market cap | $3.10M | — |
| 1-day change | -1.05% | +1.69% |
| YTD return | — | -66.14% |
| 1-year return | — | -64.54% |
| 5-year return | — | +1349.54% |
| EPS (TTM) | $-71.41 | $-0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-11.70M |
| 52-week high | $77.10 | $69.00 |
| 52-week low | $1.55 | $4.51 |
| Distance from 52-week high | -97.56% | -89.52% |
| Average volume | 2.75M | 205.08K |
| Shares outstanding | 1.65M | — |
| Employees | — | 10 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Regencell Bioscience
RGC stock →Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 10 employees
IMCC vs RGC FAQ
Are IM Cannabis and Regencell Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.